evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,973 questions · 3,072 findings · 410 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 559 · 18.2%GRADE not reported 143 · 4.7%Very low 654 · 21.3%Low 833 · 27.1%Moderate 683 · 22.2%High 200 · 6.5%

Linezolid vs no linezolid

Number of women who completed treatment ‐ total · drug‐resistant pulmonary tuberculosis

It is very uncertain whether linezolid changes treatment completed compared with no linezolid (very low certainty).

1 finding from 1 review

Linezolid vs no linezolid

Sputum culture conversion at 8 weeks · drug‐resistant pulmonary tuberculosis

It is very uncertain whether linezolid changes sputum culture conversion at 24 months compared with no linezolid (very low certainty).

1 finding from 1 review

Linezolid vs no linezolid

Antituberculous treatment discontinuationj · drug‐resistant pulmonary tuberculosis

It is very uncertain whether linezolid changes antituberculous treatment discontinuationj compared with no linezolid (very low certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Relapse · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Death from any cause · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Treatment failure · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in acquired drug resistance compared with standard 6‐month ATT regimen (low certainty).

1 finding from 1 review

Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis

Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Relapse · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Death from any cause · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review

Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen

Treatment failure · adults with drug‐sensitive pulmonary tuberculosis

Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimens (moderate certainty).

1 finding from 1 review